Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00804856 | Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia | completed | Phase 2 | 180 | Boehringer IngelheimINDUSTRY | 7 | Oct 3, 2023 | clinicaltrials |
| NCT01056523 | Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 29 | Jewish General HospitalOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT02073838 | Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | completed | Phase 2 | 23 | Sarit AssoulineOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT00081809 | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma | completed | Phase 2 | 35 | Agenus Inc.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00571493 | VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 42 | University of NebraskaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00574496 | Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00610883 | LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma | completed | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT02771197 | Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant | completed | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03571308 | A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)(ACCEPT) | completed | Phase 1 / Phase 2 | 39 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00550615 | Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 38 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01428635 | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | completed | Phase 2 / Phase 3 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03155100 | Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines(KEd) | completed | Phase 2 | 15 | Raija SilvennoinenOTHER | 2 | Sep 26, 2023 | clinicaltrials |
| NCT00352027 | Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma | completed | Phase 2 | 81 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT01336933 | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 2 | 34 | University of NebraskaOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT03625388 | Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | completed | Phase 2 | 56 | Hikma Pharmaceuticals LLCINDUSTRY | 4 | Sep 22, 2023 | clinicaltrials |
| NCT00003838 | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | completed | Phase 2 | 202 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01739309 | Study of LY2835219 for Mantle Cell Lymphoma | completed | Phase 2 | 28 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 21, 2023 | clinicaltrials |
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | completed | Phase 2 | 156 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03202628 | Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 8 | Mayo ClinicOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03309878 | Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04091490 | Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)(Nivo-DHAP) | completed | Phase 2 | 40 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00106600 | Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 12 | CTI BioPharmaINDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT01696461 | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | completed | Phase 2 | 127 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Sep 14, 2023 | clinicaltrials |
| NCT02711852 | A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) | completed | Phase 2 | 19 | SecuraBioINDUSTRY | 2 | Sep 11, 2023 | clinicaltrials |
| NCT04022005 | Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL | completed | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05082675 | Stem Cell Translpantation in Multiple Myeloma | completed | Phase 2 | 357 | European Society for Blood and Marrow TransplantationNETWORK | 11 | Sep 11, 2023 | clinicaltrials |
| NCT01346787 | Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients(CCD) | completed | Phase 2 | 58 | European Myeloma Network B.V.NETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT02642965 | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 38 | Children's Oncology GroupNETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT00004197 | Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | — | University of NebraskaOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT00572013 | Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma | completed | Phase 1 / Phase 2 | 32 | University of NebraskaOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT01882803 | A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma(DYNAMO) | completed | Phase 2 | 129 | SecuraBioINDUSTRY | 12 | Sep 7, 2023 | clinicaltrials |
| NCT02873338 | Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 75 | Jazz PharmaceuticalsINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT03390296 | OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT00006695 | Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma | completed | Phase 2 | 50 | University of NebraskaOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT00007852 | Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 44 | University of NebraskaOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT03531918 | Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm | completed | Phase 1 / Phase 2 | 66 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT04224571 | CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children | completed | Phase 2 | 208 | Chinese University of Hong KongOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT02962401 | Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia(RemodelWM3) | completed | Phase 2 | 50 | French Innovative Leukemia OrganisationOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT02597062 | High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma | completed | Phase 2 | 76 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 28, 2023 | clinicaltrials |
| NCT00101101 | Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma | completed | Phase 2 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT02340780 | Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 14 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 22, 2023 | clinicaltrials |
| NCT03542266 | CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma | completed | Phase 2 | 21 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT03903185 | Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy | completed | Phase 1 / Phase 2 | 24 | Ain Shams UniversityOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04445701 | Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 10 | Arch OncologyINDUSTRY | 1 | Aug 22, 2023 | clinicaltrials |
| NCT00039130 | Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia | completed | Phase 2 | 105 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04712942 | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | completed | Phase 2 | 14 | University of LeipzigOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT01484093 | Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 96 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT01616238 | A Study for Older Adults With Acute Lymphoblastic Leukaemia(UKALL60+) | completed | Phase 2 | 126 | University College, LondonOTHER | 2 | Aug 16, 2023 | clinicaltrials |
| NCT03882203 | CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia | completed | Phase 2 | 18 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 15, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Oct 3, 2023source: clinicaltrials